GoodRx Holdings

GDRX

Market cap $910M

GoodRx Holdings, Inc. (GDRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ARLINGTON, Va. & SANTA MONICA, Calif.--(BUSINESS WIRE)-- #HealthIT--Surescripts®, the nation's leading health intelligence network, introduces its Patient Experience product, Script Corner™, to transform the medication experience and empower patients by bringing together prescription benefit data, medication management and personalized engagement. Script Corner will include patient price transparency, including discounted cash prices through an exclusive partnership with GoodRx (Nasdaq: GDRX), the leading.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of RxSmartSaver powered by GoodRx at Giant Eagle pharmacies, giving patients a fast and easy way to access lower prices on high-cost brand medications directly at the pharmacy counter. “We are excited to partner with Giant Eagle to make brand medications more affordable and easier to access for the many patients who rely on them,” said David Graziano,.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy® pill (oral semaglutide) is now available at a cash price of $149 per month at more than 70,000 pharmacies nationwide via GoodRx. For consumers looking to easily evaluate their options for both treatment and access to the medication, they will soon be able to connect with a licensed healthcare provider through GoodRx for Weight.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for medication savings in the U.S., today announced that executives from the Company will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which GoodRx will discuss business updates. A live webcast will be available on the Compan.

Hims & Hers and GoodRx are reshaping virtual care, but which one leads in platform strategy and patient engagement? Let's dive in.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced two major initiatives to make FDA-approved GLP-1 medications more widely available. First, the launch of GoodRx for Weight Loss, a telemedicine subscription that connects consumers to licensed healthcare providers for affordable weight management treatment. Second, in partnership with Novo Nordisk, a new introductory cash price of $199 per month for Ozempic® (se.

GoodRx Holdings, Inc. ( GDRX ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Aubrey Reynolds - Director of Investor Relations Wendy Barnes - President, CEO & Director Christopher McGinnis - CFO & Treasurer Conference Call Participants Michael Cherny - Leerink Partners LLC, Research Division Daniel Grosslight - Citigroup Inc., Research Division Lisa Gill - JPMorgan Chase & Co, Research Division Jailendra Singh - Truist Securities, Inc., Research Division John Ransom - Raymond James & Associates, Inc., Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Stanislav Berenshteyn - Wells Fargo Securities, LLC, Research Division Craig Hettenbach - Morgan Stanley, Research Division Brian Tanquilut - Jefferies LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx Third Quarter 2025 Earnings Call. As a reminder, today's conference call is being recorded.

GoodRx CEO Wendy Barnes sees a “profound transformation” happening in prescription drug pricing. The catalyst, Barnes said during an earnings call Wednesday (Nov. 3), is the pending launch of TrumpRx, the planned government-run prescription drug website.

While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.